[팜뉴스=이권구 기자] Dong-A ST held its 10th regular shareholder meeting at its headquarters on the 28th and reported that it achieved sales of KRW 635.8 billion and operating profit of KRW 30.5 billion based on separate financial statements in 2022, up 7.7% and 97.0% , respectively , compared to the previous quarter A cash dividend of 700 earned per share and a stock dividend of 0.02 shares were decided.
In addition, some changes to the Articles of Incorporation proposed to amend regulations such as the dividend base date were approved in order to comply with the plan to improve the dividend procedure in accordance with global standards. (To improve shareholder value, the payment date is set after the dividend amount has been determined to increase the predictability of the dividend)
Along with this, Kim Hak-joon, CEO of Yeouido Administrative Law Firm, was reappointed as an outside director, and Jeong Jae-hoon, vice president of Dong-A Socio Holdings, was appointed as other non-executive directors.
Dong-A ST’s board of directors, which is the internal decision-making body, includes a majority of outside directors in order to improve governance transparency and shareholder value. In addition, the Appraisal and Compensation Committee and the Audit Committee, which are sub-committees within the board of directors, are all made up of outside directors, and more than two-thirds of the director recommendation committee are outside are external directors.
“Last year, there were many difficulties in the business environment due to global inflation such as rising raw material prices and steep increases in interest rates,” said Min-Young Kim, president of Dong-A ST, chairman of the shareholders’ meeting. In addition, we have secured a global research and development base by incorporating Newrobo Pharmaceuticals, a Nasdaq-listed company in Boston, USA, as a subsidiary.”
“The global popular product, Stelara biosimilar DMB-3115, plans to apply for product approval in the US and Europe in the first half of this year based on excellent phase 3 clinical results, which secured an immuno- oncology through a license agreement at the end of 2022.” He emphasized, “We will strengthen research in the field of immuno-oncology and metabolic disease treatment together with DMB-3115 to become a company that stands out in Research and Development.”